智通财经APP获悉,高盛发布研报称,维持爱康医疗(01789)买入评级,将2025-2026年每股收益(EPS)下调2.7%/3.1%,以体现对带量采购后毛利率改善持稍保守态度,并引入2027年预测。该行给予12个月目标价79港元(原目标价76港元),基于2027年预期市盈率21倍(较2024年下调,因市场波动),三年每股收益复合年增长率(CAGR)为11%(较原20%下调,因2025年基数较高)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.